Desipramine Hydrochloride

HCID 65327CAS 58-28-6

Grundinformationen

Standard-SMILES
CNCCCN1c2ccccc2CCc2ccccc21.Cl
InChIKey
XAEWZDYWZHIUCT-UHFFFAOYSA-N
Summenformel
C18H23ClN2
Durchschnittliche Molmasse
302,8 g/mol
Monoisotopische Masse
302,15497642

Überblick

Desipramine Hydrochloride is the hydrochloride salt form of desipramine, a secondary amine tricyclic antidepressant (TCA). In the central nervous system (CNS), desipramine hydrochloride blocks the re-uptake of neurotransmitters, including norepinephrine and serotonin. This leads to an increase in the amount of these neurotransmitters in the synaptic cleft and prolongs their activities postsynaptically.

Namen und Bezeichner

Bevorzugter Name
Desipramine Hydrochloride
IUPAC
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine;hydrochloride

Namen und Synonyme

Desipramine hydrochloride58-28-6Desipramine HclDMI hydrochlorideRMI 9,384ADesmethylimipramine chlorideDesimipramine, hydrochlorideNSC-114901Desipramine monohydrochlorideEX 4355Demethylimipramine hydrochlorideImipraminedemethyl hydrochloride
Weitere Namen anzeigen
G-35020Desmethylimipramine hydrochlorideJB-8181Desmethylimipramine monohydrochlorideDTXSID90469421Y58DO4MY1RMI-9384AEX-4355

Datenbank-Bezeichner

CAS
58-28-6
PubChem CID
65327
DTXSID
DTXSID9046942
ChEMBL
CHEMBL1696
UNII
1Y58DO4MY1
EC Number
200-373-1

Eigenschaften

Berechnete Struktureigenschaften

Polarare Oberfläche (TPSA)
15,3 Ų
H-Brücken-Donoren
2
H-Brücken-Akzeptoren
2
Frei drehbare Bindungen
4
Schwere Atome
21

Experimentelle und physikochemische Eigenschaften

Solubility>45.4 [ug/mL] (The mean of the results at pH 7.4)
Human Drugs · 2 Einträge

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Collision Cross Section162.1 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Sicherheit und Regulatorisches

GHS-Klassifizierung

GHS Classification · 4 Einträge

Danger

H302 (97.9%): Harmful if swallowed [Warning Acute toxicity, oral]

P233, P260, P261, P264, P264+P265, P270, P271, P272, P280, P284, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P333+P317, P337+P317, P342+P316, P362+P364, P403, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 47 reports by companies from 9 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Regulatory Information · 2 Einträge

Status: Active Update: 07-12-2017 https://echa.europa.eu/registration-dossier/-/registered-dossier/21340

5H-Dibenzb,fazepine-5-propanamine, 10,11-dihydro-N-methyl-, monohydrochloride: Does not have an individual approval but may be used under an appropriate group standard

Other Safety InformationIMAP assessments - 5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N-methyl-, monohydrochloride: Human health tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (97.9%)

Toxikologische Informationen

Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Desipramine hydrochloride

Ambiguous-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Chemie und Industrie

Pharmakologische Informationen

FDA Pharmacological Classification · 4 Einträge

DESIPRAMINE HCL

Tricyclic Antidepressant [EPC]

DESIPRAMINE HYDROCHLORIDE

Tricyclic Antidepressant [EPC]

MeSH Pharmacological Classification · 3 Einträge

Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system.

Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.

Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.

Zugehörige Reaktionen

16

Verknüpfte Notizen

Wird geladen…